In-field stereotactic body radiotherapy (SBRT) reirradiation for pulmonary malignancies as a multicentre analysis of the German Society of Radiation Oncology (DEGRO).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 02 2021
25 02 2021
Historique:
received:
20
12
2020
accepted:
29
01
2021
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Data of thoracic in-field reirradiation with two courses of stereotactic body radiotherapy (SBRT) is scarce. Aim of this study is to investigate feasibility and safety of this approach. Patients with a second course of thoracic SBRT and planning target volume (PTV) overlap were analyzed in this retrospective, multicenter study. All plans and clinical data were centrally collected. 27 patients from 8 centers have been amenable for evaluation: 12 with non-small-cell lung cancer, 16 with metastases, treated from 2009 (oldest first course) to 2020 (latest second course). A median dose of 38.5 Gy to the 65%-isodose over a median of 5 fractions was prescribed in the first course and 40 Gy in 5 fractions for the second SBRT-course. Median PTV of the second SBRT was 29.5 cm
Identifiants
pubmed: 33633130
doi: 10.1038/s41598-021-83210-3
pii: 10.1038/s41598-021-83210-3
pmc: PMC7907095
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
4590Références
Lung Cancer. 2016 Jul;97:51-8
pubmed: 27237028
Ann Palliat Med. 2014 Apr;3(2):75-91
pubmed: 25841506
Radiother Oncol. 2014 Mar;110(3):505-10
pubmed: 24444530
Cancer Treat Rev. 2015 Jun;41(6):511-8
pubmed: 25913714
Lancet Oncol. 2019 Apr;20(4):494-503
pubmed: 30770291
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):1017-23
pubmed: 22543216
Radiother Oncol. 2011 Nov;101(2):260-6
pubmed: 22056534
J Neurosurg. 2017 Jul;127(1):148-156
pubmed: 27494815
Radiother Oncol. 2016 Mar;118(3):485-91
pubmed: 26385265
J Thorac Oncol. 2017 Feb;12(2):281-292
pubmed: 27826034
Lancet Oncol. 2015 Jun;16(6):630-7
pubmed: 25981812
Radiother Oncol. 2020 Jan;142:230-235
pubmed: 31481272
Radiother Oncol. 2017 May;123(2):227-233
pubmed: 28274491
J Clin Oncol. 2019 May 20;37(15):1316-1325
pubmed: 30943123
Int J Radiat Oncol Biol Phys. 2010 Dec 1;78(5):1387-93
pubmed: 20381271
J Clin Oncol. 2006 Oct 20;24(30):4833-9
pubmed: 17050868
Radiother Oncol. 2016 Oct;121(1):1-8
pubmed: 27600155
J Thorac Oncol. 2012 Sep;7(9):1462-5
pubmed: 22895143
Radiat Oncol. 2018 Jul 28;13(1):136
pubmed: 30055636
J Cancer Res Ther. 2013 Oct-Dec;9(4):680-5
pubmed: 24518717
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084
pubmed: 30513377
Radiother Oncol. 2018 May;127(2):246-252
pubmed: 29510865
Strahlenther Onkol. 2020 May;196(5):417-420
pubmed: 32211940
World Neurosurg. 2017 Aug;104:589-593
pubmed: 28450235
PLoS One. 2018 Jun 6;13(6):e0198692
pubmed: 29874299
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):402-6
pubmed: 25017480
Radiother Oncol. 2013 Jun;107(3):423-7
pubmed: 23647748
Radiother Oncol. 2011 Nov;101(2):245-9
pubmed: 21724287